Polar Capital Holdings’s Apellis Pharmaceuticals APLS Stock Holding History

Polar Capital Holdings’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,706,510	Closed	-$93.1M	–	243
2025 Q4	$93.1M	Buy	3,706,510 +1,056,280	+40%	+$24.8M	0.36%	72
2025 Q3	$60M	Buy	2,650,230 +1,298,055	+96%	+$30.3M	0.29%	90
2025 Q2	$23.4M	Sell	1,352,175 -225,000	-14%	-$4.16M	0.12%	132
2025 Q1	$34.5M	Hold	1,577,175	–	–	0.21%	116
2024 Q4	$50.3M	Buy	1,577,175 +495,175	+46%	+$14.9M	0.28%	91
2024 Q3	$31.2M	Buy	1,082,000 +2,560	+0.2%	+$94.8K	0.15%	115
2024 Q2	$41.4M	Buy	1,079,440 +25,000	+2%	+$1.13M	0.24%	90
2024 Q1	$62M	Buy	1,054,440 +1,000	+0.1%	+$63.7K	0.33%	75
2023 Q4	$63.1M	Sell	1,053,440 -435	-0%	-$22.1K	0.39%	73
2023 Q3	$40.1M	Buy	1,053,875 +588,875	+127%	+$25.9M	0.3%	87
2023 Q2	$42.4M	Hold	465,000	–	–	0.21%	96
2023 Q1	$30.7M	Buy	465,000 +458,100	+6,639%	+$26.4M	0.2%	113
2022 Q4	$357K	Hold	6,900	–	–	﹤0.01%	300
2022 Q3	$471	Hold	6,900	–	–	﹤0.01%	342
2022 Q2	$312	Buy	+6,900	New	+$315K	﹤0.01%	370

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Polar Capital Holdings's APLS Position: Q1 2026 in Review

Polar Capital Holdings sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 3,706,510 shares — an estimated $93.1M sold.

Polar Capital Holdings first reported a position in APLS in Q2 2022 and held it in 15 quarters. The position peaked at $93.1M in Q4 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Polar Capital Holdings reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Polar Capital Holdings sold 3,706,510 Apellis Pharmaceuticals shares in Q1 2026, an estimated $93.1M.
Polar Capital Holdings first reported a position in Apellis Pharmaceuticals in Q2 2022 and held it in 15 quarters.
Polar Capital Holdings's Apellis Pharmaceuticals position peaked at $93.1M in Q4 2025.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Polar Capital Holdings's 13F filing for Q1 2026, filed 15 May 2026.